Elevance Health FY2024 Financial Report: Revenue $144.2B Up 1.0%, Net Income $5.98B

Executive Summary

Elevance Health, Inc. (NYSE: ELV) reported solid financial performance for FY2024, with total revenue reaching $144.2 billion, representing a 1.0% increase compared to FY2023. Net income stood at $5.98 billion, a slight decrease of 0.2% from the prior year, reflecting stable profitability amid market and operational adjustments. The company maintains a strong balance sheet with total assets of approximately $116.9 billion and shareholders’ equity of $41.3 billion. Cash flows from operating activities remained robust at $5.8 billion, supporting ongoing investments and shareholder returns. The company’s strategic acquisitions and disciplined capital management underpin its long-term growth outlook, despite some margin compression due to market dynamics. Overall, Elevance Health demonstrates resilience and steady growth, positioning well for future opportunities in the healthcare sector.

Key Metrics (Historical Comparison)

Management Discussion and Analysis (MD&A)

Elevance Health’s FY2024 results reflect a resilient business model with continued growth in core health benefits and pharmacy services. Revenue growth was modest but steady, driven by increased membership and premium rate adjustments. Margins faced slight pressure due to rising healthcare costs and competitive pricing pressures, yet the company’s diversified portfolio and cost management initiatives helped sustain profitability. Strategic acquisitions, including Centers and CareBridge, expanded the company’s footprint in Medicaid and long-term care, positioning it for future growth. The company’s disciplined capital allocation, including share repurchases totaling $2.9 billion and dividend payments of $1.71 per share, underscores its commitment to shareholder value. Despite macroeconomic uncertainties, Elevance Health’s strong liquidity position and diversified revenue streams support its outlook for sustainable long-term growth.

Income Statement Analysis

Revenue increased by 1.0% YoY, reaching $144.2 billion, primarily driven by membership growth and rate increases. Gross profit margins improved slightly to approximately 88.3%, reflecting effective cost controls. Operating expenses remained stable at around $20.0 billion, with a slight increase in administrative costs. Operating income was approximately $7.86 billion, a marginal decrease from the previous year, impacted by higher benefit costs. Net income was $5.98 billion, representing a net margin of about 4.1%. Earnings per share (EPS) on a diluted basis was $25.68, slightly below last year’s $25.22, due to share repurchases and minor margin pressures. The company’s financials demonstrate stable revenue generation and resilient profitability despite market headwinds.

Balance Sheet Analysis

As of December 31, 2024, total assets stood at approximately $116.9 billion, up 7.2% from $108.9 billion in FY2023. Cash and cash equivalents increased to $8.3 billion, supporting liquidity needs. Total receivables, including premiums and self-funded claims, grew modestly. Total liabilities increased to $75.5 billion, mainly due to higher long-term debt of $29.2 billion, reflecting recent bond issuances. Shareholders’ equity increased to $41.3 billion, driven by retained earnings and share repurchases. The debt-to-equity ratio remains conservative at approximately 0.71, indicating manageable leverage. The company’s strong liquidity and asset base underpin its capacity to fund growth initiatives and shareholder returns.

Cash Flow Analysis

Cash flows from operating activities were $5.8 billion, a decrease from $8.1 billion in FY2023, primarily due to higher benefit payments and operational investments. Investing activities used $5.2 billion, mainly for acquisitions and capital expenditures, including software development and property upgrades. Financing activities generated $1.2 billion, driven by bond issuances and share repurchases, offset by dividend payments of $1.5 billion. Capital expenditures totaled approximately $1.3 billion, supporting infrastructure and technology enhancements. Share repurchases of $2.9 billion and dividends reflect the company’s focus on returning value to shareholders. Overall, cash flow dynamics remain healthy, with sufficient liquidity to support strategic growth and shareholder distributions.

Ratios & DuPont Analysis

Return on Assets (ROA) is approximately 5.1%, calculated as net income ($5.98B) divided by total assets ($116.9B). Return on Equity (ROE) is about 14.5%, based on net income over shareholders’ equity ($41.3B). The net profit margin is approximately 4.1%, indicating stable profitability. Asset turnover ratio is roughly 1.24, reflecting efficient utilization of assets. The equity multiplier is about 2.83, indicating moderate leverage. The DuPont analysis suggests that profitability is driven by operational efficiency and effective capital management, with leverage playing a supportive role.

Risk Factors

Elevance Health faces regulatory risks related to healthcare laws and compliance, including potential changes in Medicaid and Medicare reimbursement policies. Market competition from other insurers and healthcare providers could pressure margins. Operational risks include integration of acquisitions, technology disruptions, and claims management challenges. Market risks involve interest rate fluctuations affecting debt costs and investment returns. Macro risks such as economic downturns, inflation, and geopolitical uncertainties could impact membership growth and healthcare costs. The company’s diversified portfolio and strong balance sheet mitigate some risks, but ongoing vigilance is essential to sustain long-term performance.

Notes & Additional Commentary

FY2024 included strategic acquisitions, notably Centers and CareBridge, which contributed to revenue growth and expanded service offerings. The company’s margin compression was partly due to rising healthcare costs and competitive pricing. Share repurchases and dividend payments demonstrate a balanced approach to capital return. Unusual items include a $201 million gain from the sale of the life and disability businesses, which enhances liquidity. The company’s disciplined capital management and strategic investments position it well for future growth, despite macroeconomic headwinds.

Investment Implications

Elevance Health’s stable revenue base, strong cash flows, and prudent capital management support a positive long-term outlook. Short-term opportunities include leveraging recent acquisitions to expand market share and improve margins. Risks include potential regulatory changes and market competition, which could impact profitability. The company’s diversified operations and solid balance sheet provide resilience. Investors should consider the company’s steady growth trajectory and focus on operational efficiency as key drivers for sustained value creation.